1. Scrip
  2. >>New Products

Lilly's Taltz Approved For AS As New Guidelines Keep TNF Inhibitors In Front Line

 
• By Mandy Jackson

VP Rebecca Morison said the ankylosing spondylitis indication adds more evidence of Taltz's benefits. She noted Lilly believes there should be fewer steps before AS patients access IL-17 inhibitors.

Ankylosing Spondylitis word, medical term word with medical concepts in blackboard and medical equipment - Image
Ankylosing spondylitis is the third US FDA-approved indication for Taltz. • Source: Shutterstock

The US Food and Drug Administration approval of a third indication for Eli Lilly & Co.'s interleukin-17 (IL-17) inhibitor Taltz (ixekizumab) in radiographic ankylosing spondylitis (AS) brings the label in line with Novartis AG's Cosentyx (secukinumab) in the same drug class, just days after new AS treatment guidelines recommended IL-17 agents after TNF inhibitors.

Taltz was approved 26 August for adults with active AS, also known as radiographic axial spondyloarthritis (r-axSpA), which affects the pelvic joints and spine leading to chronic inflammatory back pain, stiffness, and impaired function and mobility in an estimated 1.6m people in the US. The biologic also has generated positive Phase III results in non-radiographic axSpA (nr-axSpA), an indication for which Lilly plans to seek US FDA approval in 2019

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.